AIM ImmunoTech Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 1994
Net Income	-31.12	-28.96	-19.45	-19.13	-14.4	-9.4	Upgrade
Depreciation & Amortization	0.47	0.53	-0.42	0.78	0.73	0.79	Upgrade
Share-Based Compensation	0.24	0.24	0.95	1.57	1.04	0.85	Upgrade
Other Operating Activities	8.01	6.93	2.81	2.82	2.26	-1.31	Upgrade
Operating Cash Flow	-22.4	-21.27	-16.11	-13.97	-10.37	-9.07	Upgrade
Capital Expenditures	-0.03	0.05	3.81	0.2	-0.02	-0.07	Upgrade
Change in Investments	-0.29	-0.29	7.36	-0.24	-8.57	-5.78	Upgrade
Other Investing Activities	-0.59	-0.59	-0.19	-0.59	-0.57	-0.3	Upgrade
Investing Cash Flow	-0.91	-0.83	10.99	-0.63	-9.16	-6.15	Upgrade
Share Issuance / Repurchase	0.71	0.49	0.08	13.04	61.25	15.3	Upgrade
Debt Issued / Paid	2.5	0	0	-4.85	-4.69	1.08	Upgrade
Financing Cash Flow	3.21	0.49	0.08	8.19	56.56	16.39	Upgrade
Net Cash Flow	-20.1	-21.61	-5.04	-6.41	37.03	1.17	Upgrade
Free Cash Flow	-22.43	-21.22	-12.29	-13.76	-10.39	-9.14	Upgrade
Free Cash Flow Margin	-11623.83%	-10504.95%	-8719.15%	-10193.33%	-6374.23%	-6525.00%	Upgrade
Free Cash Flow Per Share	-0.45	-0.44	-0.26	-0.29	-0.33	-2.51	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).